As an investor in Xoma and a subscriber to a number of medical newsletters including Sturza and MTSL, I have found the best information and analysis comes from a letter written by the Prohost Research Group. They have a monthly (mostly) letter of about 16 pages as well as a weekly (mostly) update that contains 7 or 8 pages.They follow Xoma as well as a number of other companies such as ENZN, GNLB, BIOX,VRTX,GZTC, and some of the larger ones such as AGPH.CHIR,GENZ, etc. I have been a subscriber for a number of years and have been very happy with them.Their address is P. O. Box 640429, Oakland Gardens, NY 11364. Telephone number is 718 631 8699.
From their latest newsletter: "....Slowly but surely the stock price is stablizing forming a base from which it will be ready for the successful launch.We expect good news but remind our readers that the task of conducting trials on a large number of patients is not easy. Unlike investors, companies can't function with the market performance of their stock occupying their minds. XOMA is currently busy making a very promising product a greatly successful one."
XOMA is also currently profiled in the September issue of "Research", a magazine which is written for stockbrokers.. Michael Murphy is quoted at the beginning : "Wall Street has been slow to give XOMA credit for their success with BPI. The market value of the entire company is barely over $200 million, yet it has spent over $125 million on R&D in the last five years. With clinical trials progressing well, XOMA is the largest position in the Murphy New World Biotechnology Fund."......It is a very upbeat article.
My subscriptions to STURZA and MTSL are both up for renewal. I might not renew as a combination of SI and Prohost give me all the information I need along with a subscription to "BioCentury".
Ellis |
